Primary pulmonary hypertension between inflammation and cancer.

We believe that the monoclonal cell expansion in primary pulmonary hypertension is the result of autonomous growth of stem cell-like endothelial cells, whereas the polyclonal proliferation in secondary pulmonary hypertension occurs as a response of endothelial cells to exogenous stimuli (like viral infection or high shear stress). In this context, we propose that different transcriptional and translational events govern the growth and expansion of monoclonal when compared with polyclonal pulmonary endothelial cells. The availability of antibodies directed against specific tyrosine kinase proteins involved in vasculogenesis/angiogenesis now permits the identification and localization of the components of such a misguided angiogenesis cell proliferation program in the pulmonary hypertensive vascular lesions.

[1]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[2]  David Baunoch,et al.  Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT , 1997, Nature.

[3]  N. Voelkel,et al.  PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. , 1992, Journal of applied physiology.

[4]  J. LeónCastro,et al.  [Primary pulmonary hypertension]. , 1971, Revista clinica espanola.

[5]  G. Breier,et al.  Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. , 1992, Development.

[6]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[7]  M. Yoshida,et al.  Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.

[8]  G. Breier,et al.  Hypoxia and platelet‐derived growth factor‐BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells , 1995, FEBS letters.

[9]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[10]  N. Voelkel,et al.  Vascular Endothelial Growth Factor in Pulmonary Hypertension , 1996, Annals of the New York Academy of Sciences.

[11]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[12]  N. Voelkel,et al.  Appetite suppressants and pulmonary hypertension , 1997, Thorax.

[13]  N. Voelkel,et al.  Inflammatory mediator effects on pulmonary blood flow, edema, and the vascular endothelium , 1991 .

[14]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[15]  M. Yacoub,et al.  Lung mast cells in plexogenic pulmonary arteriopathy. , 1991, Journal of clinical pathology.

[16]  R Bicknell,et al.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.

[17]  N. Voelkel,et al.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.

[18]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[19]  Janet Rossant,et al.  A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis , 1997, Cell.

[20]  J. Rossant,et al.  Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. , 1996, Development.

[21]  Y. Fujii‐Kuriyama,et al.  Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Cantley,et al.  Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2 , 1996, Cell.

[23]  E. Mark,et al.  Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. , 1997, The New England journal of medicine.

[24]  N. Voelkel,et al.  5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[25]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[26]  M. Matsumoto,et al.  Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[28]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[29]  S. Ren,et al.  Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. , 1997, The Journal of clinical investigation.

[30]  E. Hoffman,et al.  Interstitial lung disease: A quantitative study using the adaptive multiple feature method. , 1999, American journal of respiratory and critical care medicine.

[31]  A Kahn,et al.  Interstitial lung disease. , 1982, The Journal of the Arkansas Medical Society.

[32]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.